STOCK TITAN

Glaukos (NYSE: GKOS) director updates stock option grant to $106.52 strike

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4/A

Rhea-AI Filing Summary

Glaukos Corp director Mark J. Foley reported a grant of 2,987 stock options for common stock, each with an exercise price of $106.52. These options were granted under the company’s Director Compensation Policy and vest in full on the one-year anniversary of the May 28, 2026 grant date.

This Form 4/A corrects an earlier filing that mistakenly listed the exercise price as $53.57. After this grant, Foley holds 2,987 stock options from this award, which are scheduled to expire on May 28, 2036 if not exercised.

Positive

  • None.

Negative

  • None.
Insider Foley Mark J
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 2,987 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 2,987 shares (Direct, null)
Footnotes (1)
  1. This Form 4A amends a Form 4 filed June 1, 2026 that incorrectly reported the exercise price of options granted to the Reporting Person on May 28, 2026 as $53.57. The correct exercise price for the options granted is $106.52, as shown above. Granted pursuant to the Issuer's Director Compensation Policy. Vests in full on the one-year anniversary of grant date.
Options granted 2,987 options Stock Option (Right to Buy) grant on May 28, 2026
Exercise price $106.52 per share Corrected option exercise price for this grant
Previously reported price $53.57 per share Incorrect exercise price in original Form 4
Total options after grant 2,987 options Total derivative securities following this transaction
Vesting schedule One-year cliff vest Vests in full on one-year anniversary of grant
Expiration date May 28, 2036 Option expiration if not exercised earlier
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"incorrectly reported the exercise price of options granted"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
Director Compensation Policy financial
"Granted pursuant to the Issuer's Director Compensation Policy"
vests in full financial
"Vests in full on the one-year anniversary of grant date"
Form 4A regulatory
"This Form 4A amends a Form 4 filed June 1, 2026"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Foley Mark J

(Last)(First)(Middle)
C/O GLAUKOS CORPORATION
ONE GLAUKOS WAY

(Street)
ALISO VIEJO CALIFORNIA 92656

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
GLAUKOS Corp [ GKOS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/28/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)
06/01/2026
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$106.52(1)05/28/2026A2,98705/28/2027(2)05/28/2036Common Stock2,987$02,987D
Explanation of Responses:
1. This Form 4A amends a Form 4 filed June 1, 2026 that incorrectly reported the exercise price of options granted to the Reporting Person on May 28, 2026 as $53.57. The correct exercise price for the options granted is $106.52, as shown above.
2. Granted pursuant to the Issuer's Director Compensation Policy. Vests in full on the one-year anniversary of grant date.
Diana Scherer, Attorney-in-Fact06/23/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Glaukos (GKOS) director Mark Foley report?

Mark J. Foley reported receiving 2,987 stock options for Glaukos common stock. The options were granted on May 28, 2026 under the Director Compensation Policy and represent a compensation-related equity award, not an open-market stock purchase or sale.

What is the exercise price of Mark Foley’s new Glaukos (GKOS) stock options?

The exercise price of Mark Foley’s 2,987 Glaukos stock options is $106.52 per share. This corrected price replaces a previously reported $53.57 and represents the cost per share if he chooses to exercise the options in the future.

When do Mark Foley’s Glaukos (GKOS) stock options vest and expire?

The stock options vest in full on the one-year anniversary of the May 28, 2026 grant date. They are scheduled to expire on May 28, 2036, giving Foley a 10-year window after vesting to exercise the options if he chooses.

Why did Glaukos (GKOS) file an amended Form 4/A for Mark Foley?

The amended Form 4/A corrects the exercise price of options granted to Mark Foley. An earlier filing reported a $53.57 exercise price, but the correct exercise price is $106.52, as now disclosed, while all other key grant terms remain the same.

How many Glaukos (GKOS) stock options does Mark Foley hold from this grant?

Following the reported grant, Mark Foley holds 2,987 stock options from this specific award. These options relate to Glaukos common stock, carry a $106.52 exercise price, and are part of his compensation as a director of the company.